Javier Rodriguez
Known title: Chief Executive OfficerCIK: 0001415548
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.
Transaction History
| DVA | ▼ Sell | Open Market | 39,407 | $8.2M | 6/16/2026 | View on chart |
| DVA | ▼ Sell | Open Market | 30,000 | $6.3M | 6/15/2026 | View on chart |
| GILD | ▲ Buy | Grant | 1,146 | $0 | 4/30/2026 | View on chart |
| DVA | ▲ Buy | Grant | 20,900 | $0 | 3/15/2026 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 5,165 | $628K | 11/15/2025 | View on chart |
| GILD | ▲ Buy | Grant | 1,516 | $0 | 5/7/2025 | View on chart |
| DVA | ▲ Buy | Grant | 18,822 | $0 | 3/15/2025 | View on chart |
| DVA | ▲ Buy | Grant | 37,423 | $0 | 11/15/2024 | View on chart |
| DVA | ▼ Sell | Open Market | 50,000 | $8.3M | 9/16/2024 | View on chart |
| DVA | ▼ Sell | Open Market | 9,881 | $1.6M | 9/13/2024 | View on chart |
| DVA | ▼ Sell | Open Market | 7,943 | $1.2M | 8/27/2024 | View on chart |
| DVA | ▼ Sell | Open Market | 32,176 | $5.0M | 8/26/2024 | View on chart |
| DVA | ▲ Buy | Option Exercise | 750,000 | $50.9M | 8/20/2024 | View on chart |
| DVA | ▼ Sell | Other | 334,166 | $50.9M | 8/20/2024 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 181,928 | $27.7M | 8/20/2024 | View on chart |
| GILD | ▲ Buy | Grant | 2,310 | $0 | 5/8/2024 | View on chart |
| DVA | ▲ Buy | Option Exercise | 750,000 | $50.9M | 3/6/2024 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 162,905 | $21.9M | 3/6/2024 | View on chart |
| DVA | ▼ Sell | Other | 377,646 | $50.9M | 3/6/2024 | View on chart |
| DVA | ▲ Buy | Option Exercise | 50,000 | $3.4M | 2/28/2024 | View on chart |
| DVA | ▼ Sell | Other | 26,568 | $3.4M | 2/28/2024 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 10,252 | $1.3M | 2/28/2024 | View on chart |
| DVA | ▼ Sell | Open Market | 7,397 | $938K | 2/27/2024 | View on chart |
| DVA | ▲ Buy | Option Exercise | 450,000 | $30.5M | 2/26/2024 | View on chart |
| DVA | ▼ Sell | Other | 243,574 | $30.5M | 2/26/2024 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 89,128 | $11.2M | 2/26/2024 | View on chart |
| DVA | ▼ Sell | Open Market | 67,603 | $8.5M | 2/26/2024 | View on chart |
| DVA | ▲ Buy | Option Exercise | 500,000 | $33.9M | 12/14/2023 | View on chart |
| DVA | ▼ Sell | Other | 311,581 | $33.9M | 12/14/2023 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 82,716 | $9.0M | 12/14/2023 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 15,298 | $1.5M | 5/15/2023 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 25,805 | $2.5M | 5/15/2023 | View on chart |
| DVA | ▲ Buy | Option Exercise | 88,213 | $5.8M | 5/10/2023 | View on chart |
| DVA | ▼ Sell | Other | 58,059 | $5.8M | 5/10/2023 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 13,238 | $1.3M | 5/10/2023 | View on chart |
| DVA | ▼ Sell | Open Market | 15,516 | $1.5M | 5/10/2023 | View on chart |
| DVA | ▼ Sell | Open Market | 1,400 | $140K | 5/10/2023 | View on chart |
| DVA | ▲ Buy | Grant | 58,780 | $0 | 5/10/2023 | View on chart |
| GILD | ▲ Buy | Grant | 1,887 | $0 | 5/3/2023 | View on chart |
| DVA | ▲ Buy | Option Exercise | 79,909 | $5.2M | 6/6/2022 | View on chart |
| DVA | ▼ Sell | Other | 54,111 | $5.2M | 6/6/2022 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 11,326 | $1.1M | 6/6/2022 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 17,233 | $1.7M | 5/15/2022 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 12,681 | $1.3M | 5/15/2022 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 29,076 | $2.9M | 5/15/2022 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 3,873 | $387K | 5/15/2022 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 15,298 | $1.5M | 5/15/2022 | View on chart |
| DVA | ▲ Buy | Grant | 24,890 | $0 | 5/12/2022 | View on chart |
| GILD | ▲ Buy | Grant | 2,444 | $0 | 5/5/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 2,223 | — | 5/3/2022 | View on chart |
| DVA | ▲ Buy | Grant | 28,884 | $0 | 4/22/2022 | View on chart |
| DVA | ▲ Buy | Grant | 66,230 | $0 | 4/22/2022 | View on chart |
| DVA | ▲ Buy | Grant | 14,364 | $0 | 4/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
DaVita (DVA) Discussed as Potentially Undervalued Cash Producer
Recent articles highlight DaVita as a cash-producing stock that may be undervalued relative to its earnings power. The company has outperformed the broader market recently, with one analysis noting a 58% gain. While the stock is trading near its 52-week low, analysts maintain a higher average price target, suggesting a gap between current price and long-term expectations.
DaVita (DVA) Discussed as Potentially Undervalued Cash Producer. Recent articles highlight DaVita as a cash-producing stock that may be undervalued relative to its earnings power. The company has outperformed the broader market recently, with one analysis noting a 58% gain. While the stock is trading near its 52-week low, analysts maintain a higher average price target, suggesting a gap between current price and long-term expectations.